Evoke Pharma, Inc. (EVOK)

US — Healthcare Sector
Peers: YCBD  BFRI  SBFM  SNOA  ADIL  MHUA  NRSN  SSKN  BMRA 

Automate Your Wheel Strategy on EVOK

With Tiblio's Option Bot, you can configure your own wheel strategy including EVOK - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol EVOK
  • Rev/Share 5.0114
  • Book/Share 1.7134
  • PB 6.2392
  • Debt/Equity 1.1724
  • CurrentRatio 1.3709
  • ROIC -0.5619

 

  • MktCap 18412542.0
  • FreeCF/Share -1.4183
  • PFCF -5.0846
  • PE -5.071
  • Debt/Assets 0.3193
  • DivYield 0
  • ROE -0.9948

 

  • Rating C-
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 3
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Shareholder Alert: The Ademi Firm investigates whether Evoke Pharma Inc. is obtaining a Fair Price for its Public Shareholders
EVOK
Published: November 04, 2025 by: PRNewsWire
Sentiment: Neutral

MILWAUKEE , Nov. 4, 2025 /PRNewswire/ -- The Ademi Firm is investigating Evoke (NASDAQ: EVOK) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995.

Read More
image for news Shareholder Alert: The Ademi Firm investigates whether Evoke Pharma Inc. is obtaining a Fair Price for its Public Shareholders
MAI Capital Management Announces Expanded Office of Managing Partners Appointments Following Strategic Acquisition of Evoke Advisors
EVOK
Published: November 03, 2025 by: Business Wire
Sentiment: Neutral

CLEVELAND--(BUSINESS WIRE)--Partnership creates national RIA with 600 employees and $65 billion in AUM.

Read More
image for news MAI Capital Management Announces Expanded Office of Managing Partners Appointments Following Strategic Acquisition of Evoke Advisors
Evoke Advisors Ranked No. 1 on Forbes' ‘America's Top RIA Firms' List for Fourth Consecutive Year
EVOK
Published: October 03, 2025 by: Business Wire
Sentiment: Neutral

LOS ANGELES--(BUSINESS WIRE)--Ranking recognizes Evoke's achievement in advancing client experience, and its leadership as a trusted advisor in the RIA industry.

Read More
image for news Evoke Advisors Ranked No. 1 on Forbes' ‘America's Top RIA Firms' List for Fourth Consecutive Year
MAI Capital Management Announces Strategic Partnership with Evoke Advisors
EVOK
Published: August 27, 2025 by: Business Wire
Sentiment: Neutral

CLEVELAND & LOS ANGELES--(BUSINESS WIRE)--MAI Capital Management strategically partners with Evoke Advisors. Together, the firm will manage approximately $60 billion across over 30 offices.

Read More
image for news MAI Capital Management Announces Strategic Partnership with Evoke Advisors
William Hill owner Evoke falls at the first-quarter update
EVOK
Published: March 26, 2025 by: Proactive Investors
Sentiment: Negative

Evoke PLC (LSE:EVOK) shares plummeted 18% after the William Hill owner reported annual results in line with expectations but revealed slower growth at the start of 2025. Results for the past calendar year showed revenues up 3% to £1.75 billion and reported losses before tax more than tripling to £191.4 million from £65.2 million the previous year.

Read More
image for news William Hill owner Evoke falls at the first-quarter update

About Evoke Pharma, Inc. (EVOK)

  • IPO Date 2013-09-25
  • Website https://www.evokepharma.com
  • Industry Drug Manufacturers - Specialty & Generic
  • CEO Matthew J. D'Onofrio MBA
  • Employees 3

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.